Patritumab deruxtecan for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that is hormone receptor-positive (HR+) and HER2-negative, and it has spread or cannot be removed with surgery.
- You must have already been treated with a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) along with hormone therapy, and the cancer must have grown or come back during or shortly after that treatment.
- You must have a tumor that can be measured on scans (called measurable disease per RECIST).
- You must be well enough to do light daily activities (performance status 0 or 1).
- You cannot have had certain other breast cancer treatments, like certain chemotherapies or drugs that target the HER3 protein.
- You must not have uncontrolled heart or lung problems, or a history of lung scarring (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, patritumab deruxtecan, combined with other anti-cancer drugs for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see if these combinations can shrink tumors or slow cancer growth.
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
This trial tests two targeted drugs together for people with advanced breast cancer that is hormone receptor positive and has low levels of a protein called HER2. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
This trial tests a new drug called patritumab deruxtecan for people with advanced solid tumors that have an NRG1 fusion. The drug targets a protein called HER3 on cancer cells and may help shrink tumors or slow their growth.
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.